Amina Zoubeidi

11.2k total citations
126 papers, 5.0k citations indexed

About

Amina Zoubeidi is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Amina Zoubeidi has authored 126 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Pulmonary and Respiratory Medicine, 77 papers in Molecular Biology and 43 papers in Oncology. Recurrent topics in Amina Zoubeidi's work include Prostate Cancer Treatment and Research (81 papers), Cancer, Lipids, and Metabolism (27 papers) and Clusterin in disease pathology (19 papers). Amina Zoubeidi is often cited by papers focused on Prostate Cancer Treatment and Research (81 papers), Cancer, Lipids, and Metabolism (27 papers) and Clusterin in disease pathology (19 papers). Amina Zoubeidi collaborates with scholars based in Canada, United States and United Kingdom. Amina Zoubeidi's co-authors include Martin Gleave, Alastair Davies, Ladan Fazli, Eliana Beraldi, Jennifer L. Bishop, Himisha Beltran, Daksh Thaper, Paul Toren, François Lamoureux and Anousheh Zardan and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Amina Zoubeidi

120 papers receiving 5.0k citations

Peers

Amina Zoubeidi
Hui‐Wen Lo United States
Ming‐Fong Lin United States
Elgene Lim Australia
Todd W. Miller United States
John D. Gordan United States
Andrew H. Sims United Kingdom
Sarki A. Abdulkadir United States
Trever G. Bivona United States
Hui‐Wen Lo United States
Amina Zoubeidi
Citations per year, relative to Amina Zoubeidi Amina Zoubeidi (= 1×) peers Hui‐Wen Lo

Countries citing papers authored by Amina Zoubeidi

Since Specialization
Citations

This map shows the geographic impact of Amina Zoubeidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amina Zoubeidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amina Zoubeidi more than expected).

Fields of papers citing papers by Amina Zoubeidi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amina Zoubeidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amina Zoubeidi. The network helps show where Amina Zoubeidi may publish in the future.

Co-authorship network of co-authors of Amina Zoubeidi

This figure shows the co-authorship network connecting the top 25 collaborators of Amina Zoubeidi. A scholar is included among the top collaborators of Amina Zoubeidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amina Zoubeidi. Amina Zoubeidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zoubeidi, Amina, et al.. (2025). LKB1 inactivation unleashes prostate cancer lineage plasticity. Cell Research. 35(1). 5–6.
2.
Zoubeidi, Amina, et al.. (2023). Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer. Endocrinology. 164(4). 4 indexed citations
3.
Ci, Xinpei, Jun Hao, Xin Dong, et al.. (2018). Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research. 78(10). 2691–2704. 55 indexed citations
4.
Ketola, Kirsi, et al.. (2017). Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. Clinical Cancer Research. 23(22). 6923–6933. 31 indexed citations
5.
Shrestha, Raunak, Hui Xue, Yuwei Wang, et al.. (2016). BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research. 23(6). 1542–1551. 25 indexed citations
6.
Bishop, Jennifer L., Daksh Thaper, Sepideh Vahid, et al.. (2016). The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery. 7(1). 54–71. 263 indexed citations
7.
Yamamoto, Yoshiaki, Yohann Loriot, Eliana Beraldi, et al.. (2015). Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth. Clinical Cancer Research. 21(7). 1675–1687. 105 indexed citations
8.
Lelj‐Garolla, Barbara, Masafumi Kumano, Eliana Beraldi, et al.. (2015). Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Molecular Cancer Therapeutics. 14(5). 1107–1116. 43 indexed citations
9.
Toren, Paul, Soojin Kim, Steven Pham, et al.. (2014). Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer. Molecular Cancer Therapeutics. 14(1). 59–69. 79 indexed citations
10.
Kuruma, Hidetoshi, Hiroaki Matsumoto, Masaki Shiota, et al.. (2013). A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo. Molecular Cancer Therapeutics. 12(5). 567–576. 86 indexed citations
11.
Matsumoto, Hiroaki, Yoshiaki Yamamoto, Masaki Shiota, et al.. (2013). Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Cancer Research. 73(16). 5206–5217. 60 indexed citations
12.
Thomas, Christian, François Lamoureux, Claire Crafter, et al.. (2013). Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo. Molecular Cancer Therapeutics. 12(11). 2342–2355. 115 indexed citations
13.
Shiota, Masaki, Jennifer L. Bishop, Ka Mun Nip, et al.. (2013). Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer. Cancer Research. 73(10). 3109–3119. 159 indexed citations
14.
Shiota, Masaki, Anousheh Zardan, Ario Takeuchi, et al.. (2012). Clusterin Mediates TGF-β–Induced Epithelial–Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells. Cancer Research. 72(20). 5261–5272. 127 indexed citations
15.
Kumano, Masafumi, Junya Furukawa, Masaki Shiota, et al.. (2012). Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer. Molecular Cancer Therapeutics. 11(8). 1661–1671. 47 indexed citations
16.
Lamoureux, François, Christian Thomas, Claire Crafter, et al.. (2012). Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363. Clinical Cancer Research. 19(4). 833–844. 89 indexed citations
17.
Thomas, Christian, Amina Zoubeidi, Hidetoshi Kuruma, et al.. (2011). Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo. Molecular Cancer Therapeutics. 10(2). 347–359. 48 indexed citations
18.
Lamoureux, François, Christian Thomas, Min-Jean Yin, et al.. (2011). Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer. Cancer Research. 71(17). 5838–5849. 66 indexed citations
19.
Zoubeidi, Amina, Susan Ettinger, Eliana Beraldi, et al.. (2010). Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells. Molecular Cancer Research. 8(1). 119–130. 108 indexed citations
20.
Zoubeidi, Amina, Anousheh Zardan, Eliana Beraldi, et al.. (2007). Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity. Cancer Research. 67(21). 10455–10465. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026